July 23, 2018

Prevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer Types

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

HR-DDR mutations were seen in 17.4% of tumors across 21 cancer lineages, providing a path to explore the role of HRD-directed therapies, including poly-ADP ribose polymerase inhibitors, DNA-damaging chemotherapies, and newer agents such as ATR inhibitors.

Me gusta

Guardar

Cite This Study

Heeke et al. (Mon,) studied this question.

synapsesocial.com/papers/69da11319a6164e50fa3db84 https://doi.org/https://doi.org/10.1200/po.17.00286

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology2015 · 32,255 citations
2BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients2011 · 400 citations
3Identification of frequent somatic mutations in inflammatory breast cancer2017 · 45 citations
4Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial2016 · 1,200 citations
5Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy2015 · 246 citations

Me gusta

Guardar